Abstract 232P
Background
Purpose: To evaluate the efficacy and safety of selective internal radiation therapy (SIRT) with Y-90 resin microspheres for the treatment of unresectable hepatocellular carcinoma (HCC) in Chinese population.
Methods
Data from patients with unresectable HCC treated by SIRT and followed-up for up to three months at Beijing Tsinghua Changgung Hospital between September 2022 and September 2023 were reviewed retrospectively.
Results
Data from 63 patients with unresectable HCC were analyzed. The mean age was 58.8±12.7 years, and 51 (80.95%) were men. Majority of patients were Barcelona Clinic Liver Cancer (BCLC) stage C (53.97%) and Child-Pugh class A (71.43%). At 3-month, disease control rate (DCR) was 87.3%, and ORR was 69.8%. During a median follow-up of 7.6 (range: 3.0-14.1) months, five patients died. Median PFS was 11.5 months, and the median OS had not reached. Additionally, 12 (19%) patients were downstaged with a mean time to surgery of 6.6 months. Any grades adverse events (AEs) developed in 8 (12.7%) patients and no serious AE was reported. Univariable analysis showed better tumor response for patients with ECOG 0 (p=0.015), BCLC A (p=0.048), albumin level >35g/L (p=0.036), single tumor (p=0.038), no intrahepatic metastasis(p=0.009), ≤2prior systematic treatments (p=0.006) or non-cirrhosis (p=0.009), but none of these variables was significantly in multivariable analysis. The longer PFS was observed in patients with maximum tumor diameter <10cm (p=0.016), no vascular invasion (p=0.033), no distant metastasis (p=0.0003) and achieving objective response (p=0.001) ,Which are independent prognostic factors in multivariable analysis.
Conclusions
SIRT with Y-90 resin microspheres is an effective and safe treatment for unresectable HCC in Chinese patients. Maximum tumor diameter <10cm, no vascular invasion, no distant metastasis and achieving objective response may predict longer PFS. These results should be confirmed in prospective studies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.